<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03015883</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-SCC-00</org_study_id>
    <nct_id>NCT03015883</nct_id>
  </id_info>
  <brief_title>Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma</brief_title>
  <acronym>DaRT</acronym>
  <official_title>A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Squamous Cell Carcinoma (First in Man)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha Tau Medical LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha Tau Medical LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A unique approach for cancer treatment employing intratumoral diffusing alpha radiation&#xD;
      emitter device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, first in man, controlled study, assessing the safety and efficacy&#xD;
      of diffusing alpha emitters radiation therapy (DaRT) delivered through radioactive seeds&#xD;
      inserted into the tumor.&#xD;
&#xD;
      This approach combines the advantages of local intratumoral irradiation of the tumor, as used&#xD;
      in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that&#xD;
      will be introduced in quantities considerably lower than radiation therapy already used in&#xD;
      patients.&#xD;
&#xD;
      Lesions with histopathological diagnosis of squamous cell carcinoma will be studied.&#xD;
&#xD;
      Reduction in tumor size 30 days after DaRT insertion will be assessed.&#xD;
&#xD;
      Safety will be assessed by the incidence, severity and frequency of all Adverse Events (AE).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Actual">June 25, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30-45 days post seed insertion</time_frame>
    <description>The incidence, severity and frequency of all Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in Tumor size</measure>
    <time_frame>30-45 days post seed insertion</time_frame>
    <description>The reduction in tumor size 30-45 days after DaRT insertion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of NecroticTissue</measure>
    <time_frame>30-45 days post seed insertion</time_frame>
    <description>Percent of necrotic tissue in the tumor 30 days after DaRT insertion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diffusing Alpha Radiation Emitters Therapy (DaRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed Devices</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Diffusing Alpha Radiation Emitters Therapy (DaRT)</intervention_name>
    <description>An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.</description>
    <arm_group_label>Diffusing Alpha Radiation Emitters Therapy (DaRT)</arm_group_label>
    <other_name>DaRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histopathological confirmation of squamous cell carcinoma.&#xD;
&#xD;
          2. Tumor size ≤ 5 centimeters in the longest diameter.&#xD;
&#xD;
          3. Age over 18.&#xD;
&#xD;
          4. Women of childbearing potential will have evidence of negative pregnancy test.&#xD;
&#xD;
          5. Life expectancy of more than 6 months.&#xD;
&#xD;
          6. Performance status 2 (ECOG scale) or less.&#xD;
&#xD;
          7. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumor maximal diameter &gt; 5 centimeters.&#xD;
&#xD;
          2. Tumor of Keratoacanthoma histology.&#xD;
&#xD;
          3. Performance status ≥ 3 (ECOG scale).&#xD;
&#xD;
          4. Patients with moribund diseases, autoimmune diseases or vasculitis.&#xD;
&#xD;
          5. Patients under immunosuppressive and/or corticosteroid treatment.&#xD;
&#xD;
          6. Volunteers that participated in other studies in the past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noga Kurman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davidof Cancer Institution at the Rabin Medical Center Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Davidof Cancer Institution at the Rabin Medical Center Israel</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Alpha emitting radiation</keyword>
  <keyword>Skin Cancer</keyword>
  <keyword>Carcinoma, Squamous</keyword>
  <keyword>HNSCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

